AZN
AstraZeneca PLC · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth -15.0% ·
share flow -3.5% ·
net new positions -17.6%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 156 | +6 | 601.40M | $113.10B | +11 | −4 |
| Q1 2026 | 151 | +2 | 571.10M | $111.81B | +21 | −20 |
| Q4 2025 | 148 | 0 | 438.95M | $40.35B | +2 | −1 |
| Q3 2025 | 24 | 0 | 219.30M | $16.82B | +1 | −2 |
| Q2 2025 | 22 | -1 | 189.68M | $13.26B | — | −1 |
| Q1 2025 | 21 | 0 | 171.06M | $12.57B | — | — |
| Q4 2024 | 21 | +3 | 174.28M | $11.42B | +3 | — |
| Q3 2024 | 17 | -3 | 166.39M | $12.97B | — | −3 |
| Q2 2024 | 20 | — | 172.48M | $13.45B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 62.89M | -3.1% | $4.90B | 0.6% | ▼ Trim | 2 | SEC ↗ ×2 |
| 2 | PRIMECAP Management ✦ | 41.98M | -1.4% | $3.27B | 2.4% | ▼ Trim | 2 | SEC ↗ |
| 3 | Wellington Management ✦ | 37.25M | -8.2% | $2.90B | 0.5% | ▼ Trim | 2 | SEC ↗ ×8 |
| 4 | Fisher Asset Management ✦ | 10.48M | +5.3% | $816.51M | 0.3% | ▲ Add | 2 | SEC ↗ |
| 5 | Capital World Investors ✦ | 6.25M | 0.0% | $487.25M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 6 | Soros Fund Management ✦ | 2.65M | +8.2% | $206.68M | 5.8% | ▲ Add | 2 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 1.59M | +4672.0% | $123.99M | 0.2% | ▲ Add | 2 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 1.10M | -52.0% | $85.66M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 493.45K | +0.3% | $38.44M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 448.45K | -27.4% | $34.94M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 11 | Arrowstreet Capital ✦ | 332.34K | +27.2% | $34.63M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 304.91K | +430.3% | $23.76M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Bridgewater Associates ✦ | 205.11K | -1.9% | $15.98M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 14 | Dodge & Cox ✦ | 149.03K | -0.5% | $11.61M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Norges Bank ✦ (passive) | 120.79K | 0.0% | $9.41M | 0.0% | Held | 2 | SEC ↗ |
| 16 | Millennium Management ✦ | 118.48K | +262.9% | $9.23M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 18.86K | +37.8% | $1.47M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $45.81M | was 0.1% |
| Point72 Asset Management | $38.91M | was 0.1% |
| Adage Capital Partners | $27.02M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,307 holders, 729.50M shares, $139.69B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer · See Remarks · 20 sh @ 160.57 · $3,249
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology